A Study to Determine the Effects of MK0557 in Obese Subjects (0557-006)(COMPLETED) | NCT00533598 | Trialant
CompletedInterventionalPhase 2Updated Sep 7, 2016
A Study to Determine the Effects of MK0557 in Obese Subjects (0557-006)(COMPLETED)
ClinicalTrials.gov ID
NCT00533598
Lead Sponsor
Merck Sharp & Dohme LLCINDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 2
Last Update Posted
Sep 7, 2016Estimated
Start Date
Sep 2002
Primary Completion Date
Jun 2003Actual
Completion Date
Jun 2003Actual
Brief Summary
The purpose of this study is to assess the effects of MK0557 on body weight in obese subjects.
Obesity
MK0557
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Men and women between 21 and 65 years of age, willing to avoid all prescription and nonprescription medicine to alter body weight for entire study
Exclusion Criteria:
You are or plan to become pregnant
You have smoked or used nicotine within 6 months of the study
History of abusing alcohol and/or drugs
History of a stroke, you have diabetes mellitus, you are taking medication for high blood pressure, you have had recent surgery, you have been involved in another study within 3 months of study, use of cholesterol or anti-seizure medication during the study
Have participated in a weight loss program 3 months before the study or during the course of the study